Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in overweight or obesity with type 2 diabetes
2023-506931-13-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Modality
- Peptides
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Overweight, obesity and type 2 diabetes mellitus (T2DM) comparing CagriSema with Placebo (2 arms). Primary endpoints: Relative change in body weight and Achievement of ≥ 5% weight reduction. Started Jan 2023; status: completed.
02
Drugs
CagriSema
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-506931-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506931-13-00.